Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (41-50 of 150) with videos related to

Pageof 15
Sort By:
Journal of Diabetes Science and Technology|April 30, 2011
Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopyThomas Jax, Tim Heise, Leszek Nosek, et al.
Kidney International Reports|November 29, 2023
Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 DiabetesKarsten Heusser, Jens Tank, André Diedrich, et al.
Clinical Therapeutics|February 1, 2015
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover studyTim Heise, Michaela Mattheus, Hans J Woerle, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 4, 2014
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes MellitusTim Heise, Leszek Nosek, Carsten Roepstorff, et al.
Journal of Diabetes Science and Technology|September 19, 2017
Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 DiabetesEric Zijlstra, Marek Demissie, Tina Graungaard, et al.
Diabetes, Obesity & Metabolism|June 22, 2016
Euglycaemic glucose clamp: what it can and cannot do, and how to do itTim Heise, Eric Zijlstra, Leszek Nosek, et al.
Clinical Diabetes and Endocrinology|August 15, 2021
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesitySusanna Bianzano, Tim Heise, Arvid Jungnik, et al.
Diabetes Care|February 27, 2010
Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetesChristoph Kapitza, Eric Zijlstra, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 16, 2017
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetesTim Heise, Marianne Nørskov, Leszek Nosek, et al.
Diabetes, Obesity & Metabolism|October 24, 2018
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitusUlrike Hövelmann, Minna Braendholt Olsen, Ulrik Mouritzen, et al.
Pageof 15

Showing results (41-50 of 150) with videos related to

Sort By:
Pageof 15
Journal of Diabetes Science and Technology|April 30, 2011
Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopyThomas Jax, Tim Heise, Leszek Nosek, et al.
Kidney International Reports|November 29, 2023
Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 DiabetesKarsten Heusser, Jens Tank, André Diedrich, et al.
Clinical Therapeutics|February 1, 2015
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover studyTim Heise, Michaela Mattheus, Hans J Woerle, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 4, 2014
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes MellitusTim Heise, Leszek Nosek, Carsten Roepstorff, et al.
Journal of Diabetes Science and Technology|September 19, 2017
Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 DiabetesEric Zijlstra, Marek Demissie, Tina Graungaard, et al.
Diabetes, Obesity & Metabolism|June 22, 2016
Euglycaemic glucose clamp: what it can and cannot do, and how to do itTim Heise, Eric Zijlstra, Leszek Nosek, et al.
Clinical Diabetes and Endocrinology|August 15, 2021
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesitySusanna Bianzano, Tim Heise, Arvid Jungnik, et al.
Diabetes Care|February 27, 2010
Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetesChristoph Kapitza, Eric Zijlstra, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 16, 2017
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetesTim Heise, Marianne Nørskov, Leszek Nosek, et al.
Diabetes, Obesity & Metabolism|October 24, 2018
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitusUlrike Hövelmann, Minna Braendholt Olsen, Ulrik Mouritzen, et al.
Pageof 15